Zobrazeno 1 - 10
of 148
pro vyhledávání: '"Tami Livnat"'
Autor:
Tami Livnat, Rima Dardik
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 11, p 5741 (2024)
Pro- and anticoagulant factors are core components of hemostasis [...]
Externí odkaz:
https://doaj.org/article/2a69e5e854aa4af6872c2fefce669577
Autor:
Yehonatan Weinberger, Ivan Budnik, Yael Nisgav, Dahlia Palevski, Gil Ben-David, José A. Fernández, Shany Nivinsky Margalit, Sarina Levy-Mendelovich, Gili Kenet, Dov Weinberger, John H. Griffin, Tami Livnat
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 13, p 10642 (2023)
3K3A-Activated Protein C (APC) is a recombinant variant of the physiological anticoagulant APC with cytoprotective properties and reduced bleeding risks. We studied the potential use of 3K3A-APC as a multi-target therapeutic option for choroidal neov
Externí odkaz:
https://doaj.org/article/b3454c17de6e43fd9276416c1ee5569d
Autor:
Dahlia Palevski, Gil Ben-David, Yehonatan Weinberger, Rabeei Haj Daood, José A. Fernández, Ivan Budnik, Sarina Levy-Mendelovich, Gili Kenet, Yael Nisgav, Dov Weinberger, John H. Griffin, Tami Livnat
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 22, p 14196 (2022)
3K3A-Activated Protein C (APC) is a recombinant variant of the physiological anticoagulant APC with pleiotropic cytoprotective properties albeit without the bleeding risks. The anti-inflammatory activities of 3K3A-APC were demonstrated in multiple pr
Externí odkaz:
https://doaj.org/article/fadb6be406814f558453008fe350d342
Autor:
Aliza Cassel, Nurit Rosenberg, Emad Muhammad, Tami Livnat, Rima Dardik, Miriam Berl, Meir Preis
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 5, Iss 4, Pp n/a-n/a (2021)
Abstract Background Measurement of factor VII (FVII) activity does not enable prediction of bleeding tendency in individuals with inherited FVII deficiency. Objective To characterize the molecular and functional features of FVII in a family with FVII
Externí odkaz:
https://doaj.org/article/b3b9c4f2f7a74719b869f97c77ef23fe
Autor:
Omri Cohen, Nitsan Landau, Einat Avisahai, Tami Brutman-Barazani, Ivan Budnik, Tami Livnat, Keren Asraf, Ram Doolman, Sarina Levy-Mendelovich, Orly Efros, Uri Manor, Eyal Meltzer, Gad Segal, Galia Rahav, Gili Kenet
Publikováno v:
Acta Haematologica. 146:151-160
Introduction: Coronavirus disease 2019 (COVID-19) disease is associated with coagulopathy and an increased risk of thrombosis. An association between thrombin generation (TG) capacity, disease severity, and outcomes has not been well described. Metho
Publikováno v:
Indian Journal of Ophthalmology, Vol 66, Iss 2, Pp 238-243 (2018)
Purpose: The aim of this study was to evaluate an innovative approach for closing retinal tears using DuraSeal™ (DS) hydrogel sealant in a rabbit model. Methods: Retinal detachment with a small tear was performed on 20 New Zealand rabbits. Thereaft
Externí odkaz:
https://doaj.org/article/9ae18a30dedd47668f53fe3dd044f281
Autor:
Sarina Levy-Mendelovich, Tami Brutman-Barazani, Ivan Budnik, Einat Avishai, Assaf A. Barg, Tamara Levy, Mudi Misgav, Tami Livnat, Gili Kenet
Publikováno v:
Journal of Clinical Medicine, Vol 10, Iss 19, p 4303 (2021)
Emicizumab (Hemlibra™) is approved for prophylaxis of hemophilia A (HA) patients. The HAVEN studies addressed bleeding reduction in emicizumab-treated patients, but real-world data on bleeding patterns during emicizumab therapy are lacking. We aime
Externí odkaz:
https://doaj.org/article/37ae0e40a6c846e2abe43dd8fffa40af
Autor:
Rima Dardik, Einat Avishai, Shadan Lalezari, Assaf A. Barg, Sarina Levy-Mendelovich, Ivan Budnik, Ortal Barel, Yulia Khavkin, Gili Kenet, Tami Livnat
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 16, p 9074 (2021)
Introduction: Hemophilia A (HA) is an X-linked bleeding disorder caused by factor VIII (FVIII) deficiency or dysfunction due to F8 gene mutations. HA carriers are usually asymptomatic because their FVIII levels correspond to approximately half of the
Externí odkaz:
https://doaj.org/article/178ae0304d984c758781f63a64fb6bad
Autor:
Tami Livnat, Yehonatan Weinberger, José A. Fernández, Alaa Bashir, Gil Ben-David, Dahlia Palevski, Sarina Levy-Mendelovich, Gili Kenet, Ivan Budnik, Yael Nisgav, John H. Griffin, Dov Weinberger
Publikováno v:
Biomolecules, Vol 11, Iss 3, p 358 (2021)
The activated protein C (APC) ability to inhibit choroidal neovascularization (CNV) growth and leakage was recently shown in a murine model. A modified APC, 3K3A-APC, was designed to reduce anticoagulant activity while maintaining full cytoprotective
Externí odkaz:
https://doaj.org/article/257408fbd8ea498eaece922f8cc88963
Autor:
D. Bashari, Einat Avishai, Tami Brutman-Barazani, Tami Livnat, Gili Kenet, Amir A. Kuperman, Mudi Misgav, Ivan Budnik, Assaf A. Barg, Aaron Lubetsky
Publikováno v:
Haemophilia. 27:383-391
Introduction Real-world data on prophylaxis of severe haemophilia A (HA) patients treated by emicizumab are scarce. Aim To study the efficacy and safety of longitudinal emicizumab prophylaxis and assess laboratory monitoring correlations in a large p